0
Influenza Pseudoviral Neutralization Assay Kit

$1,200.00

Influenza Pseudoviral Neutralization Assay Kit

Kit Includes:

  • 5 mL of Pseudovirus Particles
  • 1 Tube of Ready-To-Use Target Cells (5 Million Cells/Tube)
  • 15 mL of VBI Infection Medium
  • 2 mL of Lysis Buffer
  • 3.5 mL of Firefly Luciferase Assay Buffer

Kit Does Not Include Standard Neutralizing Antibody – Available as an Add-On
 RCSNAK-01

In stock
Add to wishlist
Add to wishlist
Strain A/Brevig-Mission/1/1918(H1N1), A/Victoria/4897/2022(H1N1), A/California/04/2009(H1N1), A/PR/8/1934(H1N1), A/Wisconsin/67/2022(H1N1), A/Croatia/10136RV/2023(H3N2), A/Darwin/9/2021(H3N2), A/District of Columbia/27/2023(H3N2), A/California/LACPHL‑INF02051/2025(H3N2) Subclade K, A/Texas/37/2024(H5N1) Clade 2.3.4.4b, A/Nevada/10/2025 (H5N1) Clade 2.3.4.4b, A/Thailand/NBL1/2006(H5N1), A/Jiangsu/1/2013(H7N9), B/Austria/1359417/2021, B/Phuket/3073/2013
N/A

Product Description

Product Description

Influenza A and B Neutralization Assay Kits

Utilizing Our NEW Hybrid Alphavirus Pseudovirus Technology.

Now with ready-to-use cells! No need to culture cells or CO2 incubators. Cells come pre-counted so just thaw and go.

Virongy’s Pseudoviral Neutralization Assay Kit is superior due to the implementation of our newly developed alpha pseudovirus. Alpha pseudoviruses are a newly developed and patented pseudovirus with an alphavirus-derived RNA genome for rapid expression of reporter genes (luciferase or GFP) in target cells (Hetrick et al., 2022).  Alpha-pseudovirus for Influenza A (IAV) and Influenza B viruses (IBV) are assembled with the Hemagglutinin (HA), Neuraminidase (NA), Nucleoprotein (NP), Matrix (M1), and Ion Channel (M2). The alpha-pseudoviruses are single-cycle viruses with self-amplifying RNA for rapid quantification of neutralizing antibodies, seroconversion, seroprotection, and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry.

Applications:
  • Rapid Anti-IAV/IBV drug screening
  • Rapid Anti-IAV/IBV neutralizing antibody screening
  • Determination of seroconversion and seroprotection

    • Seroconversion: The process by which a person develops detectable antibodies in the blood in response to an infection or vaccination. It marks the point at which the immune system begins to produce a measurable immune response, indicating that the body has recognized the pathogen.

    • Seroprotection: The level of antibodies in the bloodstream that is considered sufficient to protect against infection. It is often used as a measure of the effectiveness of a vaccine or immune response, indicating that a person has enough antibodies to prevent illness if exposed to the pathogen. For influenza, a serum neutralization titer of 1:40 or greater at a 50% inhibition of viral infectivity is commonly considered a protected titer

Available Strains: 

  • Influenza A/Brevig-Mission/1/1918(H1N1)__AF116575.1
  • Influenza A/California/04/2009(H1N1)__GQ117044.1
  • Influenza A/Victoria/4897/2022 (H1N1)__OQ718989.1
  • Influenza A/Wisconsin/67/2022(H1N1)__EPIISL15928563
  • Influenza A/PR/8/1934(H1N1)__XSG40873.1
  • Influenza A/Croatia/10136RV/2023(H3N2)__EPIISL19296516
  • Influenza A/Darwin/9/2021(H3N2)__OR567121.1
  • Influenza A/District of Columbia/27/2023(H3N2)__EPIISL18937823
  • Influenza A/California/LACPHL‑INF 02051/2025(H3N2)__EPIISL20263415
  • Influenza A/Thailand/NBL1/2006(H5N1)__KJ907470.1
  • Influenza A/Texas/37/2024 (H5N1)__PP577943.1
  • Influenza A/Nevada/10/2025(H5N1)__EPIISL19726293
  • Influenza A/Jiangsu/1/2013(H7N9)__KF278745.1
  • Influenza B/Austria/1359417/2021__EPIISL983345
  • Influenza B/Phuket/3073/2013__EPIISL161843

Need a strain not listed here? Ask us about a custom alpha-pseudovirus for your project. For inquiries, please reach out to us via email: info@virongy.com

Background:

Different from commonly used pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, alpha pseudoviruses are assembled with all of the structural proteins of the target virus. These particles contain a reporter genome derived from an alphavirus-based vector for rapid (4 hours) and robust expression of reporter genes. Alpha pseudoviruses represent a major technological advancement in the development of pseudoviruses and serve as a platform for rapid and robust quantification of neutralization assays, viral mutants, and antiviral drugs (Dabbagh et al., 2021; He et al., 2021).

Virongy offers pre-assembled reporter pseudovirions and variants. We also help customers to perform antiviral drug screening and quantification of neutralizing antibodies. For more information, please contact us by email: info@virongy.com

Alpha pseudovirus major advances

  • A simple protocol that is easier than an ELISA-based method
  • Higher Accuracy than a traditional ELISA-based neutralization assay
  • Faster speed compared to other pseudoviruses– (Maximum reporter expression between 12-18 hours)
  • More robust reporter signal – Alpha pseudoviruses take advantage of an alphavirus vector’s rapid and robust gene expression capacity for reporter expression.
  • High fidelity in particle structure – Alpha pseudoviruses contain all of the virus structural proteins but no structural proteins from other viruses.
  • A strong correlation with the live virus in neutralizing antibody assays. 

Want to read more on the Alpha pseudovirus technology? Click Here

Documents

Neutralizing Antibody Assay Kit – Handbook
Ready To Use Target Cells – MSDS

Related products